Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C71015
http://purl.obolibrary.org/obo/NCIT_C71015
|
|---|---|
| Preferred Name | Conatumumab |
| Definitions |
A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin. |
|---|---|
| prefLabel | Conatumumab
|
| label | Conatumumab
|
| PDQ_Closed_Trial_Search_ID | 573083
|
| code | C71015
|
| Has_Target | |
| prefixIRI | NCIT:C71015
|
| in_subset |
See more
See less
|
| Display_Name | Conatumumab
|
| Preferred_Name | Conatumumab
|
| FDA_UNII_Code | 1P48L61KM0
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Conatumumab
|
| CAS_Registry | 896731-82-1
|
| NCI_Drug_Dictionary_ID | 573083
|
| Legacy Concept Name | Anti-TRAIL_Receptor_2_Monoclonal_Antibody_AMG_655
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 573083
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C2346822
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |